Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating osimertinib and gefitinib in EGFR T790M-positive advanced non-small cell lung cancer
ACTRN12617000720314Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of osimertinib and gefitinib in non-small cell lung cancer (NSCLC), sponsored by University of Sydney. Primary endpoint: Progression-free survival rate. Started Sep 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12617000720314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000720314.